Meeting
2023 ASCO Annual Meeting
Association between pCR, TILs, and Ki-67 at baseline and after 2 weeks in patients with triple-negative breast cancer (TNBC) treated with atezolizumab and chemotherapy +/- a preceding atezolizumab monotherapy window: A translational analysis of the neoMono trial.
Authors
Ramona Erber
Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany
Ramona Erber , Hans-Christian Kolberg , Johannes Schumacher , Michael Braun , Peter A. Fasching , Eva-Maria Grischke , Christian Schem , Michael Patrick Lux , Mustafa Deryal , Oliver Hoffmann , Bernhard Heinrich , Georg Kunz , Kristina Luebbe , Petra Krabisch , Arndt Hartmann , Philip Raeth , Sabine Kasimir-Bauer , Cornelia Kolberg-Liedtke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 595)
DOI
10.1200/JCO.2023.41.16_suppl.595
Abstract #
595
Poster Bd #
425
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association of 27-gene IO score with outcome in a phase Ib trial of pembrolizumab (pembro) plus chemotherapy (CT) in metastatic triple-negative breast cancer (mTNBC).
First Author: David B. Page
Poster
2020 ASCO Virtual Scientific Program
CONTESSA TRIO: A multinational, multicenter, phase (P) II study of tesetaxel (T) plus three different PD-(L)1 inhibitors in patients (Pts) with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly pts with HER2-metastatic breast cancer (MBC).
First Author: Sara M. Tolaney
Poster
2020 ASCO Virtual Scientific Program
PREDIX II HER2: Improving pre-operative systemic therapy for human epidermal growth factor receptor 2 (HER2) amplified breast cancer (BC).
First Author: Renske Kornalijnslijper-Altena
Poster
2020 Genitourinary Cancers Symposium
FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations.
First Author: Arvind Chaudhry